Marinus Pharmaceuticals (MRNS) Research Coverage Started at Laidlaw

Laidlaw assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $18.00 price objective on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. BidaskClub cut Marinus Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, December 7th. JMP Securities reissued an outperform rating and issued a $11.00 target price (up from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th. Finally, ValuEngine cut Marinus Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, December 1st.

Shares of Marinus Pharmaceuticals (NASDAQ MRNS) traded down $1.44 during trading hours on Thursday, reaching $7.89. The company’s stock had a trading volume of 3,606,517 shares, compared to its average volume of 1,708,788. Marinus Pharmaceuticals has a fifty-two week low of $0.83 and a fifty-two week high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.02.

Several hedge funds have recently bought and sold shares of MRNS. Granite Point Capital Management L.P. lifted its position in shares of Marinus Pharmaceuticals by 250.3% during the 3rd quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock valued at $15,760,000 after buying an additional 1,918,400 shares in the last quarter. Perceptive Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at about $8,527,000. Jennison Associates LLC lifted its position in shares of Marinus Pharmaceuticals by 98.0% during the 3rd quarter. Jennison Associates LLC now owns 1,606,733 shares of the biopharmaceutical company’s stock valued at $9,432,000 after buying an additional 795,068 shares in the last quarter. Iguana Healthcare Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at about $1,027,000. Finally, EAM Investors LLC purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at about $554,000. 49.77% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Marinus Pharmaceuticals (MRNS) Research Coverage Started at Laidlaw” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/12/17/marinus-pharmaceuticals-mrns-research-coverage-started-at-laidlaw.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply